Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680677 · ClinicalTrials.gov registry record
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
A clinical trial of MDS and Leukemia, Acute, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT03680677: Recruiting study of MDS and Leukemia, Acute, sponsored by Abramson Cancer Center at Penn Medicine.
NCT03680677 is a study of MDS and Leukemia, Acute that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 20 participants, below the 96-participant average among 22 other MDS trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03680677, a study of MDS and Leukemia, Acute, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
Primary Outcome
NRM will be defined as death without evidence of disease progression or relapse.
Conditions Studied
Interventions
- PROCEDURE Bone Marrow or Peripheral Blood Graft (BMT)
- OTHER Cancer-directed Therapy or Best Supportive Care
- DIAGNOSTIC_TEST Frailty Assessment
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-09-21 |
| Est. Completion | 2026-11 |
What NCT03680677 shows while recruiting
NCT03680677 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 96-participant average among 22 other MDS trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with MDS appearing as the primary indexed condition, and to 3 interventions - of which Bone Marrow or Peripheral Blood Graft (BMT) is the first listed.
NCT03680677 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03680677 about?
NCT03680677 is a clinical study titled "Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies". The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
What is the current status of trial NCT03680677?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2018-09-21. Estimated completion is 2026-11.
What conditions does trial NCT03680677 study?
This clinical trial studies the following conditions: MDS, Leukemia, Acute.
What interventions are being tested in trial NCT03680677?
The interventions under investigation include: Bone Marrow or Peripheral Blood Graft (BMT) (PROCEDURE), Cancer-directed Therapy or Best Supportive Care (OTHER), Frailty Assessment (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03680677?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03680677 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03680677's enrollment target sits among peer trials
20 19th of 22 higher than 3 of 22 other MDS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other MDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 1
-
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI